key: cord-0724742-zfp4qw01 authors: Wu, Henry H L; Li, Jennifer W C; Bow, Andrew; Woywodt, Alexander; Ponnusamy, Arvind title: Acute interstitial nephritis following SARS-CoV-2 vaccination date: 2021-12-08 journal: Clin Kidney J DOI: 10.1093/ckj/sfab253 sha: ebc2f136164d928586030a5ad6229b0b1460a021 doc_id: 724742 cord_uid: zfp4qw01 nan We read with interest the recent publication by Czerlau et al. [1] on a series of patients with acute interstitial nephritis (AIN) following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. We have recently reported a similar case and noted a further case by de la Flor et al. [2, 3] . Unver et al. [4] reported a case of AIN with concurrent nephrotic syndrome after SARS-CoV-2 vaccination. Here, we would like to report two additional cases. The first patient is a 69-year-old female patient with rheumatoid arthritis, Sjøgren's syndrome, hypertension and hypothyroidism who presented with polyuria 5 days after the first dose of the Oxford-AstraZeneca SARS-CoV-2 (ChAdOx1 nCoV-19) vaccine. Regular medications included methotrexate, folic acid, ramipril, thyroxine and paroxetine, as well as lansoprazole on an 'as required' basis, although the patient did not take any in the last month. The physical examination was unremarkable. Blood tests revealed acute kidney injury (AKI) with an increased serum creatinine at 245 μmol/L (baseline is 85 μmol/L). The only other abnormality noted was peripheral eosinophilia. Urine dipstick did not show proteinuria or haematuria. Renal ultrasound and immunology screen were both normal. The patient was started on intravenous fluids, with ramipril and methotrexate being discontinued. Renal biopsy showed a florid interstitial infiltrate with eosinophils, with no glomerular abnormalities and no chronic interstitial damage. The patient was commenced on steroids (prednisolone 60 mg daily). Serum creatinine improved to 90 μmol/L and peripheral eosinophilia resolved. She continued to take paroxetine and thyroxine on discharge, though ramipril, lansoprazole and methotrexate were not restarted. One month following this admission, the patient re-presented with serum creatinine at 250 μmol/L and a reoccurrence of peripheral eosinophilia. On this occasion, paroxetine was stopped, and the patient was recommenced on oral steroids (prednisolone 60 mg daily). A month later, and whilst on prednisolone 20 mg daily, the patient's serum creatinine has fallen to 130 μmol/L, and peripheral eosinophilia has once again resolved. The second patient is a 60-year-old female patient who presented generally unwell 2 weeks after her second dose of the ChAdOx1 nCoV-19. The patient had a history of hypertension, and was on atorvastatin, losartan, bisoprolol and lansoprazole. Blood tests showed AKI with a serum creatinine of 754 μmol/L (baseline is 59 μmol/L). Urine dipstick did not show proteinuria or haematuria, but albumin:creatinine and protein: creatinine ratios were 20 and 166 mmol/μmol, respectively, suggestive of tubular proteinuria. Renal ultrasound, immunology and virology were normal. The patient received intravenous fluids and losartan was stopped. Renal biopsy showed widespread interstitial infiltrates in keeping with AIN. The patient was given a single dose of 250 mg intravenous methylprednisolone followed by an oral prednisolone course at 30 mg daily. When last seen, she was well and serum creatinine was 216 μmol/L. To our knowledge, 10 cases of AIN after the SARS-CoV-2 vaccination have now been reported worldwide (Table 1) , and clinicians should be aware of these reports. Czerlau et al. [1] speculated as to the underlying pathophysiology. AIN associated with other vaccines has been described previously [5, 6] . It is very difficult to prove causality in the cases described here and those reported previously. Widespread SARS-CoV-2 vaccination is continuing worldwide, and many patients presenting with AKI will therefore have a history of preceding vaccination. We also acknowledge other potential triggers of AIN in our two cases, in particular the concurrent use of proton-pump inhibitors. However, underreporting is also possible, and clinicians may regard recent vaccination as almost universal and therefore not elicit a detailed vaccination history. It is also possible that milder cases resolve spontaneously and do not undergo renal biopsy. We suggest that clinicians take note of a possible association and obtain a detailed vaccination history when confronted with cases of otherwise unexplained AIN. Approved consent has been achieved from both of the patients described in this manuscript. Acute interstitial nephritis after mRNA-based vaccination Acute interstitial nephritis following SARS-CoV-2 virus vaccination A case of acute interstitial nephritis following the Pfizer--BioNTech COVID-19 vaccine Nephrotic syndrome and acute kidney injury following CoronaVac anti-SARS-CoV-2 vaccine A case of acute tubulointerstitial nephritis possibly associated with influenza HA vaccine Vaccine-associated kidney diseases: a narrative review of the literature A.W. is member of the CKJ editorial board. The results presented in this paper have not been published previously in whole or in part.